Score Overview
Explore the 2021 public Archive ranking →
Where Halozyme Therapeutics Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- HALO
2009: 61.7% · 2021: 3.7% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 111.56 | — |
1 Year2025-09-29 | $ 73.29 | 52.22% |
5 Years2021-09-29 | $ 39.65 | 181.36% |
10 Years2016-09-29 | $ 11.90 | 9x |
20 Years2006-09-29 | $ 2.65 | 42x |
All Time2004-03-16 | $ 4.25 | 26x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2004-03-16 |
|---|---|---|---|---|---|---|
| Price | $ 111.56 | $ 73.29 | $ 39.65 | $ 11.90 | $ 2.65 | $ 4.25 |
| Return | — | 52.22% | 181.36% | 9x | 42x | 26x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1.66B | $ 413M | $ 231M |
| 2025 | $ 1.39B | $ 316M | $ 142M |
| 2024 | $ 1.01B | $ 444M | $ 596M |
| 2023 | $ 829M | $ 281M | $ 336M |
| 2022 | $ 660M | $ 202M | $ 362M |
| 2021 | $ 443M | $ 402M | $ 740M |
| 2020 | $ 267M | $ 129M | $ 368M |
| 2019 | $ 195M | -$ 72M | $ 421M |
| 2018 | $ 151M | -$ 80M | $ 354M |
| 2017 | $ 316M | $ 62M | $ 469M |
| 2016 | $ 146M | -$ 103M | $ 204M |
| 2015 | $ 135M | -$ 32M | $ 108M |
| 2014 | $ 75M | -$ 68M | $ 135M |
| 2013 | $ 54M | -$ 83M | $ 71M |
| 2012 | $ 42M | -$ 53M | $ 99M |
| 2011 | $ 56M | -$ 19M | $ 52M |
| 2010 | $ 13M | -$ 53M | $ 83M |
| 2009 | $ 13M | -$ 58M | $ 67M |
| 2008 | $ 8M | -$ 48M | $ 63M |
| 2007 | $ 3M | -$ 23M | $ 97M |
| 2006 | $ 981.75K | -$ 14M | $ 44M |
| 2005 | $ 127.21K | -$ 13M | $ 19M |
| IPO2004 | -$ 9M | $ 16M |
Halozyme Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 267M to $ 1.39B and net income grew from $ 129M to $ 316M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 135M to $ 1.39B and net income went from -$ 32M to $ 316M. Revenue increased in 9 of those 10 years; net income in 7.
Halozyme Therapeutics Inc currently holds a 20-year HDB Score of 6.5 out of 10. How the HDB Score is calculated.
Membership
Continue HALO’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
